RTS,S/AS01E

BIOLOGICAL2 trials

Sponsors

KEMRI-Wellcome Trust Collaborative Research Program, GlaxoSmithKline

Conditions

Malaria

Phase 2

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

CompletedNCT03162614

GlaxoSmithKlineMalaria

Start: 2017-05-24End: 2018-09-24Updated: 2020-10-27

Unknown Phase

An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial

KEMRI-Wellcome Trust Collaborative Research ProgramMalaria

Start: 2009-02-28End: 2016-08-31Target: 450Updated: 2015-12-07

Related Papers

Identification of RTS,S/AS01 vaccine–induced humoral biomarkers predictive of protection against controlled human malaria infection

JCI Insight2024-10-075 citations

A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults

The Journal of Infectious Diseases2020-07-1744 citations

Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children

New England Journal of Medicine2016-06-29414 citations

Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure.

2013-03-01215 citations